Poly Medicure Q2 FY27 Results: Consolidated Net Profit ₹95.13 Crore on Total Income of ₹600 Crore
- Earnings
- medical devices
Reviewed byRachit TripathiBlacklitt Research
Poly Medicure (NSE: POLYMED) reported consolidated total income of ₹599.53 crore and net profit of ₹95.13 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹508.71 crore and net profit of ₹92.03 crore, it said in a filing on 05 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹599.53 crore, up 25.5% YoY and 7.3% QoQ
- Net profit and EPS: ₹95.13 crore, up 3.6% YoY and 11.6% QoQ; basic EPS ₹9.38
- Finance costs: ₹7.15 crore, up 140.5% YoY from ₹2.97 crore
- Exceptional item: ₹9.56 crore derecognition of contingent consideration, included in profit
Standalone
The company on its own, without its subsidiaries
- Total income: ₹508.71 crore, up 13.0% YoY and 10.7% QoQ
- Net profit and EPS: ₹92.03 crore, up 3.3% YoY and 4.4% QoQ; basic EPS ₹9.08
- Other income: ₹20.44 crore, down 39.4% YoY from ₹33.72 crore
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 599.53 | 477.83 | +25.5% | 558.77 | +7.3% | |
| Revenue from operations | 580.53 | 443.88 | +30.8% | 525.38 | +10.5% |
| Other income | 19.01 | 33.94 | -44.0% | 33.40 | -43.1% |
| 95.13 | 91.80 | +3.6% | 85.27 | +11.6% | |
| Profit before tax | 125.46 | 121.69 | +3.1% | 117.31 | +6.9% |
| Finance costs | 7.15 | 2.97 | +140.5% | 6.50 | +10.0% |
| Depreciation | 35.05 | 25.04 | +39.9% | 36.25 | -3.3% |
| Tax expense | 30.33 | 29.89 | +1.5% | 32.03 | -5.3% |
| Net profit margin | 15.87% | 19.21% | -3.34 pp | 15.26% | +0.61 pp |
| EPS, basic (₹) | 9.38 | 9.06 | +3.5% | 8.49 | +10.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit grew more slowly than total income in the year, rising 3.6% against 25.5%.
Profit before tax rose 3.1%, and the consolidated profit includes an exceptional item of ₹9.56 crore (₹956.21 lacs), the derecognition of contingent consideration payable by a step-down subsidiary to the Selling Shareholders of the Pendracare Group. The company says the derecognition was on account of non-achievement of the agreed milestone for an earn-out payment under the Share Purchase Agreement.
Finance costs of ₹7.15 crore are 1.2% of total income, against 0.6% a year earlier. Depreciation rose 39.9% to ₹35.05 crore. Tax expense of ₹30.33 crore is 24.2% of profit before tax.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 508.71 | 450.26 | +13.0% | 459.74 | +10.7% | |
| Revenue from operations | 488.28 | 416.54 | +17.2% | 431.10 | +13.3% |
| Other income | 20.44 | 33.72 | -39.4% | 28.64 | -28.6% |
| 92.03 | 89.05 | +3.3% | 88.12 | +4.4% | |
| Profit before tax | 123.08 | 118.01 | +4.3% | 118.64 | +3.7% |
| Finance costs | 4.00 | 2.78 | +43.6% | 4.38 | -8.8% |
| Depreciation | 27.26 | 24.26 | +12.3% | 26.47 | +3.0% |
| Tax expense | 31.05 | 28.96 | +7.2% | 30.52 | +1.8% |
| Net profit margin | 18.09% | 19.78% | -1.69 pp | 19.17% | -1.08 pp |
| EPS, basic (₹) | 9.08 | 8.79 | +3.3% | 8.69 | +4.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 3.3%, slower than total income of 13.0% and slower than profit before tax of 4.3%. Revenue from operations rose 17.2% to ₹488.28 crore, while other income fell 39.4% to ₹20.44 crore.
Standalone finance costs of ₹4.00 crore are 0.8% of total income, and tax expense of ₹31.05 crore is 25.2% of profit before tax of ₹123.08 crore. Consolidated net profit of ₹95.13 crore is ₹3.10 crore above standalone net profit of ₹92.03 crore.
Poly Medicure is a medical devices company. Its latest quarter before this one, Q1 FY27, reported consolidated net profit of ₹85.27 crore, so the quarter ended 30 Sep 2026 shows net profit up 11.6% on that base.
The statutory auditors issued an unmodified review report on both sets of results. The company says Himalayan Mineral Waters Private Limited was consolidated effective 1 Apr 2026.
Inference
The filing states that the cash flow statement for the half year shows dividend paid, including unclaimed dividend transferred, of ₹32.29 crore. It does not say whether a dividend has been declared for the quarter.
The filing does not state the amount of the earn-out consideration or the milestone terms, and it does not give a reason for the rise in consolidated finance costs against the year-ago quarter.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
